Abstract
Fluorescence in situ hybridization (FISH) has been widely used as a diagnostic and/or prognostic tool in the field of clinical laboratory diagnosis, especially in field of hematologic malignancies. However, atypical findings that are less or not encountered during an assay validation can pose diagnostic challenges. In this presentation, we'd like to share our experience using CBFB breakapart FISH as an example. From January 1, 2000 to May 31, 2021, a total of 2809 CBFB Breakapart FISH tests were performed in 1629 cases with acute myeloid leukemia (AML) in our institute, and 16.1% (n=262), 75.7% (n=1234) and 8.2% (n=133) cases were reported as positive, normal and abnormal respectively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
